Grade III Meningioma
3
1
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
11 treatments under study, led by Qualityoflife Assessment
Research Leaders
5 sponsors active, led by National Cancer Institute (NCI)
Related Conditions
Often studied with 20 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
Research Network
Common Treatments
- Qualityoflife Assessment2
- Laboratory Biomarker Analysis1
- Aldesleukin1
- Photon Beam Radiation Therapy1
- Electric Field Therapy1
Active Sponsors
- National Cancer Institute (NCI)2
- NovoCure Ltd.1
- Northwestern University1
- Emory University1
- City of Hope Medical Center1
Top Investigators
City of Hope Medical Center
Emory University Hospital/Winship Cancer Institute
Northwestern University
Related Conditions
- Grade Ii Meningioma2
- Gliosarcoma1
- Brain Tumor1
- Mixed Glioma1
- Grade I Meningioma1